LEASE AGREEMENTLease Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 30th, 2020 Company IndustryTHIS LEASE AGREEMENT is made as of this 24th day of August, 2017, between ARE-MA REGION NO. 45, LLC, a Delaware limited liability company (“Landlord”), and FOGHORN THERAPEUTICS INC., a Delaware corporation (“Tenant”).
SIGILON THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 30th, 2020 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 23, 2020, by and among (i) Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), (ii) each of the Investors (as defined below) listed on Schedule A hereto, (iii) each person who hereafter becomes a party to this Agreement in accordance with Subsection 6.1 or Subsection 6.9 hereof, and (iv) solely with respect to Section 4 and Section 6, the Massachusetts Institute of Technology (“MIT”).
SEVERANCE WAIVER AND LETTER AGREEMENT AMENDMENTSeverance Waiver and Letter Agreement • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 30th, 2020 Company IndustryWHEREAS, Sigilon Therapeutics, Inc. (the “Company”) and (the “Executive”) entered into a letter agreement dated for the purpose of establishing the terms and conditions of Executive’s employment (the “Letter Agreement”);
SEVERANCE WAIVER AND OFFER LETTER AMENDMENTSeverance Waiver and Offer Letter • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 30th, 2020 Company IndustryWHEREAS, Sigilon Therapeutics, Inc. (the “Company”) and Rogerio Vivaldi Coelho (the “Executive”) entered into a letter agreement dated April 23, 2018 for the purpose of establishing the terms and conditions of Executive’s employment (the “Letter Agreement”);
Wednesday, May 8, 2019 Glenn Reicin glenn@grevrockbiomed.com Dear Glenn,Sigilon Therapeutics, Inc. • October 30th, 2020 • Pharmaceutical preparations
Company FiledOctober 30th, 2020 IndustryOn behalf of Sigilon Therapeutics (the “Company”), a Flagship Pioneering Company, I am delighted to make this conditional offer of employment with the Company. This offer letter (the “Offer Letter”) and the accompanying documents and agreements summarize and set forth important terms about your employment with the Company.
ASSIGNMENT AND ASSUMPTION OF LEASEAssignment and Assumption of Lease • October 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 30th, 2020 Company Industry JurisdictionThis ASSIGNMENT AND ASSUMPTION OF LEASE (this “Assignment”), dated as of October 21, 2019, is made and entered into by and among FOGHORN THERAPEUTICS INC., a Delaware corporation (“Assignor”) and SIGILON THERAPEUTICS, INC., a Delaware corporation (“Assignee”).
CONSENT TO ASSIGNMENT AND FIRST AMENDMENT TO LEASESigilon Therapeutics, Inc. • October 30th, 2020 • Pharmaceutical preparations
Company FiledOctober 30th, 2020 IndustryThis Consent to Assignment and First Amendment to Lease (this “Consent”) is made as of October 21, 2019, between and among ARE-MA REGION NO. 45, LLC, a Delaware limited liability company (“Landlord”), FOGHORN THERAPEUTICS INC., a Delaware corporation (“Tenant”), and SIGILON THERAPEUTICS, INC., a Delaware corporation (“Assignee”), with reference to the following Recitals.